{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:21:27Z","timestamp":1761488487899},"reference-count":149,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,2,12]],"date-time":"2008-02-12T00:00:00Z","timestamp":1202774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The efficacy of treatment against hepatitis C virus has improved, but it is still far from ideal. Thus, new antihepatitis C virus therapies are required.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To evaluate the data on antihepatitis C virus approaches beyond the current standard combination of pegylated interferon\u2010alpha and ribavirin.<\/jats:p><jats:p><jats:bold>Method\u2002<\/jats:bold> We reviewed the available literature regarding novel antihepatitis C virus options, given alone or in combination with existing agents.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> New interferons and ribavirin alternatives have been tried aiming to improve the efficacy and the safety\/tolerability profile of standard agents. The hepatitis C virus polymerase and NS3\/4A protease have been rather popular targets for new antihepatitis C virus agents. The combination of such inhibitors with pegylated interferon\u2010alpha and ribavirin seems to act synergistically and to prevent viral resistance, compared to monotherapies. Several novel immunomodulators are currently evaluated and may be useful in combination therapies. Alternative strategies (inhibition of hepatitis C virus protein translation, assembly\/release or binding) or agents with different modes of action (statins, <jats:italic>S<\/jats:italic>\u2010adenosylmethionine and herbs) need further evaluation.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Many novel promising antihepatitis C virus agents are being developed, offering hope for future therapies that may target multiple points of the viral life cycle and\/or host immune response. Newer approaches should ideally provide safe, effective and more tolerable therapy to all chronic hepatitis C virus patients.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2008.03644.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T14:24:39Z","timestamp":1279895079000},"page":"866-884","source":"Crossref","is-referenced-by-count":16,"title":["Review article: novel therapeutic options for chronic hepatitis C"],"prefix":"10.1111","volume":"27","author":[{"given":"E.","family":"CHOLONGITAS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. V.","family":"PAPATHEODORIDIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9506"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00522.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360703"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504296102"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04077"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.005"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2461"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.005"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.79967-0"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvi.2005.02.004"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.01.032"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.05.074"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.5.2119-2129.2001"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.06.001"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328010a869"},{"issue":"1","key":"e_1_2_6_17_2","first-page":"826A","article-title":"Daily consensus interferon versus peg\u2010interferon alfa2b with weight based or 800\u2003mg ribavirin in treatment\u2010naive patients with chronic hepatitis C genotypes 2 or 3","volume":"46","author":"Rahman F","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_18_2","first-page":"826A","article-title":"Daily consensus interferon versus peg\u2010interferon alfa2b with weight based ribavirin in treatment naive patients with chronic hepatitis C genotype 1","volume":"46","author":"Rahman F","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_19_2","first-page":"390A","article-title":"PEG\u2010IFN alfa\u20102a plus ribavirin is superior compared to high dose consensus interferon (CIFN) and ribavirin in the treatment of patients with chronic hepatitis C","volume":"46","author":"Witthoeft T","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.021"},{"issue":"1","key":"e_1_2_6_21_2","first-page":"311A","article-title":"The direct trial (daily dose consensus interferon and ribavirin: efficacy of combined therapy): treatment of non\u2010responders to previous pegylated interferon plus ribavirin sustained virologic response data","volume":"46","author":"Bacon B","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_22_2","first-page":"608A","article-title":"Treatment of hepatitis C patients with Child A and B cirrhosis with consensus interferon and ribavirin in a low ascending dosing regimen leads to significant viral elimination","volume":"44","author":"Kaiser P","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_23_2","first-page":"608A","article-title":"Extended treatment of 72 vs 48\u2003weeks for chronic hepatitis C patients with genotype 1 and high viral load using consensus interferon and ribavirin","volume":"44","author":"Kaiser P","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_24_2","first-page":"830A","article-title":"U.S. multicenter pilot study of daily consensus interferon (Infergen) plus ribavirin for difficult to treat HCV genotype 1 patients: tolerance and on therapy virologic response","volume":"46","author":"Ho SB","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.037002"},{"issue":"1","key":"e_1_2_6_26_2","first-page":"613A","article-title":"Favorable pharmacokinetics of albumin\u2010interferon alpha 2b in subjects with chronic hepatitis C","volume":"44","author":"Fiscella M","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_27_2","first-page":"317A","article-title":"Sustained virologic response rates with albinterferon alfa\u20102b plus ribavirin treatment in IFN\u2010naive, chronic hepatitis C genotype 1 patients","volume":"46","author":"Zeuzem S","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_28_2","first-page":"256A","article-title":"Sustained virologic response with albinterferon alpha\u20102b\/ribavirin treatment in prior interferon therapy non\u2010responders","volume":"46","author":"Nelson D","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)61609-2"},{"issue":"1","key":"e_1_2_6_30_2","first-page":"851A","article-title":"A phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of escalating single doses of R7025, a novel pegylated interferon compared to placebo and peginterferon 2a (40KD) (PEGASYS) in healthy volunteers","volume":"46","author":"Brennan B","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_31_2","first-page":"863A","article-title":"Phase 2a study to evaluate the safety and tolerability and anti\u2010viral of 4 doses of a novel controlled release interferon alfa 2b (Locteron) given every 2\u2003weeks for 12\u2003weeks in treatment naive patients with chronic hepatitis C (genotype 1)","volume":"46","author":"Dzyublyk I","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"e_1_2_6_33_2","first-page":"680","article-title":"Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin","volume":"3","author":"Watson J","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki405"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(06)80739-7"},{"issue":"1","key":"e_1_2_6_36_2","first-page":"610A","article-title":"Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon alpha\u20102b in the treatment of chronic HCV","volume":"44","author":"Jacobson I","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62230-2"},{"issue":"1","key":"e_1_2_6_38_2","first-page":"616A","article-title":"Rapid virologic response (RVR) is enhanced by higher drug exposure among patients receiving taribarin in combination with pegylated interferon alpha\u20102b for the treatment of HCV infection","volume":"44","author":"Shiffman M","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62187-4"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62224-7"},{"issue":"1","key":"e_1_2_6_41_2","first-page":"615A","article-title":"Effect of an IMPDH inhibitor, Merimepodib (MMPD), assessed alone and in combination with ribavirin, on HCV replication: implications regarding ribavirin\u2019s mechanism of action","volume":"44","author":"Hezode C","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_42_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/135965350501000503","article-title":"A randomized, double\u2010blind, placebo\u2010controlled dose\u2010escalation trial of merimepodib (VX\u2010497) and interferon\u2010alpha in previously untreated patients with chronic hepatitis C","volume":"10","author":"McHutchison J","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(04)90492-8"},{"issue":"1","key":"e_1_2_6_44_2","first-page":"342A","article-title":"Randomized double\u2010blind placebo\u2010controlled trial of peginterferon alfa\u20102a (40KD) and ribavirin with and without 400MG amantadine\u2010sulphate for 48\u2003weeks in treatment naive HCV genotype 1 infected patients","volume":"46","author":"Von Wagner M","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.05.019"},{"issue":"1","key":"e_1_2_6_46_2","first-page":"540A","article-title":"Absence of effect of pegylated interferon alpha\u20102b on the pharmacokinetics of valopicitabine (NM283) in patients with chronic hepatitis C","volume":"44","author":"Zhou X","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_47_2","first-page":"223A","article-title":"Valopicitabine (NM283) plus peg\u2010interferon in treatment \u2010naive hepatitis C patients with HCV genotype\u20101 infection: HCV RNA clearance during 24\u2003weeks of treatment","volume":"44","author":"Lawitz E","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)61604-3"},{"issue":"1","key":"e_1_2_6_49_2","first-page":"533A","article-title":"In vitro antiviral interactions of a novel HCV inhibitor R1479 with interferon 2a, ribavirin and other HCV inhibitors","volume":"44","author":"Jiang W","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62201-6"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21400"},{"issue":"1","key":"e_1_2_6_52_2","first-page":"311A","article-title":"Robust synergistic antiviral effect of R1626 in combination with peginterferon alpha\u20102a (40KD) with or without ribavirin \u2010interim analysis results of phase 2a study","volume":"46","author":"Pockros P","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_53_2","first-page":"813A","article-title":"A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1 infected treatment naive patients","volume":"46","author":"Le Pogam S","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_54_2","first-page":"862A","article-title":"Antiviral activity pharmacokinetics safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor following multiple ascending oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy","volume":"46","author":"Reddy R","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_55_2","first-page":"236A","article-title":"Discovery, characterization and anti\u2010HCV activity of a novel NS5A inhibitor","volume":"44","author":"Wagner R","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"e_1_2_6_56_2","first-page":"A748","article-title":"Antiviral activity of the non\u2010nucleoside polymerase inhibitor, HCV\u2010796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double\u2010blind, placebo\u2010controlled, ascending multiple dose study","volume":"130","author":"Chandra P","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_6_57_2","first-page":"607A","article-title":"Analysis of HCV NS5B genetic variants following monotherapy with HCV\u2010796, a non nucleoside polymerase inhibitor, in treatment naive HCV infected patients","volume":"44","author":"Villano S","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)61648-1"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62184-9"},{"issue":"1","key":"e_1_2_6_60_2","first-page":"534A","article-title":"In vitro resistance studies of AG\u2010021541, a novel non\u2010nucleoside inhibitor of the hepatitis C virus RNA\u2010dependent RNA polymerase","volume":"44","author":"Shi S","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2004.07.003"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62188-6"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62192-8"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62200-4"},{"issue":"1","key":"e_1_2_6_65_2","first-page":"864A","article-title":"Antiviral activity of the non\u2010nucleoside polymerase inhibitor, VCH\u2010759, in chronic hepatitis C patients: results from a randomized double blind placebo controlled ascending multiple dose study","volume":"46","author":"Cooper C","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_66_2","first-page":"255A","article-title":"Antiviral, pharmacokinetic and safety data for CS\u20109190, a non\u2010nucleoside HCV NS5B polymerase inhibitor, in a phase\u20101 trial in HCV genotype 1 infected subjects","volume":"46","author":"Bavisotto L","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_67_2","first-page":"855A","article-title":"GS\u20109190, a novel substituted imidazopyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants","volume":"46","author":"Vliegen I","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_68_2","first-page":"858A","article-title":"ANA598, a novel non\u2010nucleoside inhibitor of NS5B polymerase, exhibits favorable pharmacokinetic properties in multiple preclinical species","volume":"46","author":"Kirkovsky L","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62181-3"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)61611-0"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.116"},{"key":"e_1_2_6_72_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1128\/AAC.43.2.347","article-title":"Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV\u2010vaccinia virus recombinant","volume":"43","author":"Zhang H","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.12.001"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01496-06"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-006-0905-x"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300186"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04080"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119097"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.12.7519-7528.1995"},{"key":"e_1_2_6_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.01.009"},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.002"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1813-1822.2006"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62190-4"},{"key":"e_1_2_6_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62197-7"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)61610-9"},{"issue":"1","key":"e_1_2_6_86_2","first-page":"234A","article-title":"Final results of a phase 1b, multiple dose study of VX950, a hepatitis C virus protease inhibitor","volume":"44","author":"Reesink H","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_87_2","first-page":"614A","article-title":"Current status of subjects receiving peginterferon\u2010alpha 2a (PEG\u2010IFN) and ribavirin (RBV) after a 14\u2010day study of the hepatitis C protease inhibitor telaprevir (VX950) with PEG\u2010IFN","volume":"44","author":"Forestier N","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_88_2","first-page":"819A","article-title":"Final results of patients receiving peg\u2010interferon\u2010alfa\u20102a (PEG\u2010IFN) and ribavirin (RBV) after a 14\u2010day study of the hepatitis C protease inhibitor telaprevir (VX950) with PEG\u2010IFN","volume":"46","author":"Weegink CJ","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_89_2","first-page":"255A","article-title":"Telaprevir resistance mutations in patients with hepatitis C who relapsed after sequential therapy with telaprevir, Peg\u2010interferon alpha 2a and ribavirin","volume":"46","author":"Forestier N","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62207-7"},{"key":"e_1_2_6_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21781"},{"issue":"1","key":"e_1_2_6_92_2","first-page":"532A","article-title":"Current status of subjects receiving peg\u2010interferon\u2010alpha 2a (PEG\u2010IFN) and ribavirin (RBV) follow on therapy after 28\u2010day treatment with hepatitis C protease inhibitor telaprevir (VX950), PEG\u2010IFN and RBV","volume":"44","author":"Rodrigues\u2010Torres M","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_93_2","first-page":"314A","article-title":"Final results of patients treated with peginterferon\u2010alpha 2a (PEG\u2010IFN) and ribavirin (RBV) follow\u2010on therapy after 28\u2010day treatment with the hepatitis C protease inhibitor telaprevir (VX\u2010950), PEG\u2010IFN and RBV","volume":"46","author":"Rodrigues\u2010Torres M","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_94_2","first-page":"315A","article-title":"Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa\u20102a and ribavirin in treatment naive subjects with hepatitis C","volume":"46","author":"Jacobson I","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_95_2","first-page":"268A","article-title":"PROVE2: Phase II study of VX950 (telaprevir) in combination with peginterferon alpha\u20102a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis","volume":"46","author":"Hezode C","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_96_2","first-page":"862A","article-title":"Evaluation of viral variants during a phase 2 study (PROVE 2) of telaprevir with peginterferon alfa\u20102a and ribavirin in treatment naive HCV genotype 1 infected patients","volume":"46","author":"Kieffer T","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_97_2","first-page":"535A","article-title":"Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH503034, in an oral capsule formulation","volume":"42","author":"Zhang J","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_98_2","first-page":"233A","article-title":"Antiviral activity of SCH503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype\u20101 patients refractory to pegylated interferon (PEG\u2010IFN)","volume":"42","author":"Zeuzem S","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_99_2","first-page":"535A","article-title":"SCH 503034, a mechanism based inhibitor of hepatitis C virus NS3 protease suppresses polyprotein maturation and enhances the antiviral activity of interferon alpha\u20102b","volume":"42","author":"Malcolm B","year":"2005","journal-title":"Hepatology"},{"key":"e_1_2_6_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.012"},{"issue":"2","key":"e_1_2_6_101_2","first-page":"835A","article-title":"Pharmacokinetic analysis and liver concentrations of a series of macrocyclic peptidomimetic inhibitors of HCV NS3\/4A protease: identification of ITMN 191, a potent NS3\/4A protease inhibitor with high liver exposure across multiple species","volume":"130","author":"Rieger R","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"e_1_2_6_102_2","first-page":"834A","article-title":"Preclinical characteristics of ITMN 191, an orally active inhibitor of the HCV NS3\/4A protease nominated for preclinical development","volume":"130","author":"Seiwert S","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_6_103_2","first-page":"855A","article-title":"Genotype coverage of the HCV NS3\/4A protease inhibitor ITMN\u2010191(R7227): biochemical data reveals potent inhibition and slow dissociation with genotype 1\u20106 proteases","volume":"46","author":"Ravi Rajagopalan PT","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_104_2","first-page":"534A","article-title":"In vitro synergistic antiviral activity of ITMN\u2010191, an orally active inhibitor of the hepatitis C virus NS3\/4A protease, in combination with PEG\u2010IFN alpha 2a","volume":"44","author":"Tan H","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_105_2","first-page":"823A","article-title":"Results of a phase I placebo controlled trial in healthy volunteers to examine the safety tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing","volume":"46","author":"Verloes R","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_106_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi047437u"},{"issue":"2","key":"e_1_2_6_107_2","first-page":"A784","article-title":"Results of a phase II dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype\u20101 patients","volume":"130","author":"Yoshida E","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_6_108_2","first-page":"236A","article-title":"Entry inhibitor GNS 037 exhibits potent anti\u2010HCV activity in vitro","volume":"44","author":"Halfon P","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.08.019"},{"key":"e_1_2_6_110_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20839"},{"issue":"1","key":"e_1_2_6_111_2","first-page":"533A","article-title":"Pharmacokinetics, safety and tolerability of the isatoribine oral prodrug ANA975 in a phase 1 healthy volunteer study","volume":"42","author":"Kerr B","year":"2005","journal-title":"Hepatology"},{"key":"e_1_2_6_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.025"},{"issue":"1","key":"e_1_2_6_113_2","first-page":"224A","article-title":"Early viral response and on treatment response to CPG10101, in combination with pegylated interferon and\/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response","volume":"44","author":"Jacobson I","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62247-8"},{"key":"e_1_2_6_115_2","first-page":"274","article-title":"Histamine dihydrochloride","volume":"2","author":"Maxamine S","year":"1999","journal-title":"Drugs R D"},{"key":"e_1_2_6_116_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00378.x"},{"key":"e_1_2_6_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"issue":"1","key":"e_1_2_6_118_2","first-page":"332A","article-title":"Triple combination therapy with histamine dihydrochloride, interferon alpha\u20102b (IFN) and ribavirin for chronic hepatitis C treatment\u2010failures: 48\u2003week results","volume":"34","author":"Lurie Y","year":"2001","journal-title":"Hepatology"},{"key":"e_1_2_6_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2004.03634.x"},{"key":"e_1_2_6_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70134-X"},{"key":"e_1_2_6_121_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50242"},{"issue":"1","key":"e_1_2_6_122_2","first-page":"534A","article-title":"Assessment of the pharmacological activity of pegylated recombinant interleukin\u201029 in cynomolgus monkeys","volume":"44","author":"Freeman J","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_123_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50474"},{"issue":"1","key":"e_1_2_6_124_2","first-page":"251A","article-title":"Immunization with the therapeutic hepatitis C virus peptide vaccine IC41 in 66 chronic hepatitis C non\u2010responders patients","volume":"40","author":"Manns M","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_125_2","first-page":"533A","article-title":"Development of a universal T\u2010cell vaccine candidate for hepatitis C applicable to the majority of human HLA types and HCV genotypes","volume":"44","author":"Goossens V","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_126_2","first-page":"533A","article-title":"Circulating HLA class I restricted T cells specific for epitopes included in a candidate therapeutic vaccine","volume":"44","author":"Van de Aa A","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_127_2","first-page":"237A","article-title":"Dentritic cell based immunization by targeting HCV\u2010NS5 directly to dendritic cells in vivo using microbeads as vehicle","volume":"44","author":"Wintermeyer P","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_128_2","first-page":"312A","article-title":"Characterization of a novel approach for HCV immunization using splenic derived dendritic cells which phagocytosed HCV NS5 coated magnetic beads","volume":"44","author":"Gehring S","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.11.080"},{"key":"e_1_2_6_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.11.041"},{"key":"e_1_2_6_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21587"},{"key":"e_1_2_6_132_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21102"},{"issue":"1","key":"e_1_2_6_133_2","first-page":"534A","article-title":"Preclinical evaluation of SCY\u2010635, a cyclophilin inhibitor with potent ant\u2010HCV activity","volume":"44","author":"Houck D","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_6_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.05.014"},{"key":"e_1_2_6_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.03.059"},{"key":"e_1_2_6_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)62206-5"},{"issue":"1","key":"e_1_2_6_137_2","first-page":"816A","article-title":"HCV\u2010specific cellular immunity, RNA reductions, and normalization of ALT in chronic HCV subjects after treatment with GI\u20105005, a yeast\u2010based immunotherapy targeting NS3 and Core: a randomized, double\u2010blind, placebo controlled phase 1b study","volume":"46","author":"Schiff ER","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_138_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio742"},{"issue":"1","key":"e_1_2_6_139_2","first-page":"368A","article-title":"Benzafibrate treatment for chronic hepatitis C after failure of previous combination therapy with interferon and ribavirin","volume":"46","author":"Weich V","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_140_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21232"},{"key":"e_1_2_6_141_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21554"},{"key":"e_1_2_6_142_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21116"},{"key":"e_1_2_6_143_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000174023.73472.29"},{"key":"e_1_2_6_144_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03078.x"},{"key":"e_1_2_6_145_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.02.038"},{"key":"e_1_2_6_146_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.015"},{"issue":"1","key":"e_1_2_6_147_2","first-page":"827A","article-title":"A 52\u2003week multi\u2010centre randomized double\u2010blind placebo\u2010controlled trial evaluating the efficacy and safety of glycyrrhizin in patients with chronic hepatitis C not responding to IFN or PEG\u2010IFN plus ribavirin therapy","volume":"46","author":"Manns MP","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_148_2","first-page":"316A","article-title":"Interim data from a randomized controlled trial of nitazoxanide\u2010peginterferon\u2010ribavirin, nitazoxanide\u2010peginterferon and peginterferon\u2010ribavirin in the treatment of patients with chronic hepatitis C genotype 4","volume":"46","author":"Rossignol JF","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_6_149_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21664"},{"issue":"1","key":"e_1_2_6_150_2","first-page":"818A","article-title":"PF\u201003491390 inhibits liver fibrosis in patients with chronic hepatitis C virus infection via suppression of pro\u2010apoptotic caspase\u2010activation","volume":"46","author":"Burgess G","year":"2007","journal-title":"Hepatology"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2008.03644.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2008.03644.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:58:26Z","timestamp":1697201906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2008.03644.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,12]]},"references-count":149,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1365-2036.2008.03644.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03644.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,12]]}}}